FDA Approved: NEXLETOL — Supplemental Application (Esperion Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Nexletol (bempedoic acid) from Esperion Therapeutics, Inc., expanding the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• Nexletol (bempedoic acid)

Snippet

SUPPL AP for NEXLETOL (BEMPEDOIC ACID)